Anika Receives FDA Approval for Cosmetic Tissue Enhacement Product
by H.S. Ayoub
BioHealthInvestor.com
Shares of Anika Therapeutics (ANIK) are up more than 5% in pre-market action on Thursday after the company announced that it had received final market approval from the FDA for its Cosmetic Tissue Augmentation (CTA) product.
The company jumped 20% back on November 28 after receiving an approvable letter from the FDA, and in that press release the company expected a final approval by year's end. They were right!
CTA is an injectable form of hyaluronic acid that fills in tissue underneath the outer skin surface, giving a tighter more youthful appearance.
Anika has been seeing a surge in its revenue and profit numbers over the last three years fro its currently approved products. These include, OrthoVisc, a treatment
for osteoarthritis of the knee; Hyvisc, a treatment for equine osteoarthritis; and Amvisc and Amvisc Plus, HA viscoelastic products for ophthalmic surgery.
Adding CTA could bolster the company's sales significantly by 2008, as the marketing of the product is expected by mid 2007.
Shares of Anika Therapeutics were trading at $14.09 in pre-market trading.
__________
Related BHI articles:
- Anika Therapeutics: Keep an Eye on the Chart
- Anika Therapeutics Jumps 20% on FDA Letter
__________
BioHealthInvestor.com
Shares of Anika Therapeutics (ANIK) are up more than 5% in pre-market action on Thursday after the company announced that it had received final market approval from the FDA for its Cosmetic Tissue Augmentation (CTA) product.The company jumped 20% back on November 28 after receiving an approvable letter from the FDA, and in that press release the company expected a final approval by year's end. They were right!
CTA is an injectable form of hyaluronic acid that fills in tissue underneath the outer skin surface, giving a tighter more youthful appearance.
Anika has been seeing a surge in its revenue and profit numbers over the last three years fro its currently approved products. These include, OrthoVisc, a treatment
for osteoarthritis of the knee; Hyvisc, a treatment for equine osteoarthritis; and Amvisc and Amvisc Plus, HA viscoelastic products for ophthalmic surgery.
Adding CTA could bolster the company's sales significantly by 2008, as the marketing of the product is expected by mid 2007.
Shares of Anika Therapeutics were trading at $14.09 in pre-market trading.
__________
Related BHI articles:
- Anika Therapeutics: Keep an Eye on the Chart
- Anika Therapeutics Jumps 20% on FDA Letter
__________
posted by Nico at
8:37 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home